Spots Global Cancer Trial Database for cd22
Every month we try and update this database with for cd22 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | NCT03262298 | Leukemia Lymphoma | Anti-CD22-CAR-t... | 18 Years - 65 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04648475 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | NCT04556669 | Solid Tumor, Ad... Cervical Cancer Sarcoma NSCLC | Autologous aPD-... | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | NCT02935153 | Leukemia Lymphoma | Anti-CD22-CAR-t... | 14 Years - 75 Years | Southwest Hospital, China | |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04649983 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies | NCT03125577 | B-cell Malignan... | 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... 4SCAR19 and 4SC... | 6 Months - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04649983 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | NCT05168748 | Acute Lymphobla... | IMJ995 single a... | 1 Year - | Novartis | |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | NCT04648475 | Leukemia, B-cel... Lymphoma, B-Cel... | CD19 and CD22 t... | 3 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT04782193 | B Cell Lymphoma | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University | |
| Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma | NCT02581878 | Lymphoma, Non-H... | BAY1862864 | 18 Years - | Bayer | |
| A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia | NCT03330691 | Leukemia Lymphoma | Patient-derived... | - 30 Years | Seattle Children's Hospital | |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | NCT04088890 | B-ALL B-cell Non Hodg... DLBCL Follicular Lymp... | Fludarabine Cyclophosphamid... CD22 CAR | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
